July 7, 2025 10:39 AM EDT
R&D
Manufacturing

Com­pro­mised drug lot im­pacts Jasper's chron­ic hives study, stock falls

Max Gelman

Senior Editor

Jasper Ther­a­peu­tics’ stock crashed on Mon­day morn­ing af­ter the biotech said is­sues with a drug prod­uct lot im­pact­ed da­ta in a Phase 1b/2a clin­i­cal tri­al …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Apogee re­ports Phase 2 win for eczema drug that could chal­lenge Dupix­ent and Ebglyss

De­spite de­lay, KalVista wins FDA ap­proval af­ter Makary's short-lived at­tempt to in­ter­vene

Co­gent’s mas­to­cy­to­sis drug hits ‘home run’ in reg­is­tra­tional mid-stage tri­al

De­nal­i's Hunter syn­drome ther­a­py gets pri­or­i­ty re­view; LENZ inks Cana­da deal

No­var­tis' Cosen­tyx fails Phase 3 study for au­toim­mune dis­ease

sponsored

Un­cov­er­ing the Po­ten­tial of Tar­get­ing the CD38 Path­way for Im­mune-Me­di­at­ed Dis­eases

A service from the Financial Times